MX2023012325A - Anticuerpos anti-tslp modificados. - Google Patents
Anticuerpos anti-tslp modificados.Info
- Publication number
- MX2023012325A MX2023012325A MX2023012325A MX2023012325A MX2023012325A MX 2023012325 A MX2023012325 A MX 2023012325A MX 2023012325 A MX2023012325 A MX 2023012325A MX 2023012325 A MX2023012325 A MX 2023012325A MX 2023012325 A MX2023012325 A MX 2023012325A
- Authority
- MX
- Mexico
- Prior art keywords
- modified anti
- tslp antibodies
- tezepelumab
- tslp
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/246—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163178915P | 2021-04-23 | 2021-04-23 | |
| PCT/US2022/025999 WO2022226342A2 (en) | 2021-04-23 | 2022-04-22 | Modified anti-tslp antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023012325A true MX2023012325A (es) | 2023-10-30 |
Family
ID=81597885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023012325A MX2023012325A (es) | 2021-04-23 | 2022-04-22 | Anticuerpos anti-tslp modificados. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240182558A1 (enExample) |
| EP (1) | EP4326762A2 (enExample) |
| JP (1) | JP2024516595A (enExample) |
| KR (1) | KR20230175245A (enExample) |
| CN (1) | CN117177992A (enExample) |
| AR (1) | AR125404A1 (enExample) |
| AU (1) | AU2022262006A1 (enExample) |
| BR (1) | BR112023022041A2 (enExample) |
| CA (1) | CA3216700A1 (enExample) |
| CL (1) | CL2023003124A1 (enExample) |
| IL (1) | IL307439A (enExample) |
| MX (1) | MX2023012325A (enExample) |
| TW (1) | TW202304980A (enExample) |
| WO (1) | WO2022226342A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12110324B2 (en) | 2022-07-22 | 2024-10-08 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP) |
| WO2024118542A1 (en) * | 2022-11-28 | 2024-06-06 | Takeda Vaccines, Inc. | A method for the quantitative determination of human serum albumin monomer in virus-containing pharmaceutical compositions |
| WO2024146630A1 (zh) * | 2023-01-06 | 2024-07-11 | 江苏恒瑞医药股份有限公司 | 一种tslp抗体治疗哮喘的方法 |
| TW202448501A (zh) | 2023-02-02 | 2024-12-16 | 美商麥迪紐有限責任公司 | 用抗ｔｓｌｐ抗體治療慢性鼻竇炎 |
| WO2024238877A1 (en) | 2023-05-18 | 2024-11-21 | Medimmune, Llc | Treatment of corticosteroid dependent asthma with anti-tslp antibody |
| IL330343A (en) | 2024-01-05 | 2026-08-01 | Medimmune Llc | Treatment of chronic obstructive pulmonary disease using an anti-TSLP antibody |
| WO2025221247A1 (en) | 2024-04-17 | 2025-10-23 | Amgen Inc. | Treatment of eosinophilic esophagitis with anti-tslp antibody |
| WO2025265071A1 (en) * | 2024-06-21 | 2025-12-26 | Paragon Therapeutics, Inc. | Antibodies that bind tslp and methods of use |
| WO2026086808A1 (zh) * | 2024-10-22 | 2026-04-30 | 海南先声药业有限公司 | 抗tslp抗体及其应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| EP1847602B1 (en) * | 2005-01-12 | 2014-04-23 | Kyowa Hakko Kirin Co., Ltd. | STABILIZED HUMAN IgG2 ANTIBODIES |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| US8359965B2 (en) | 2007-09-17 | 2013-01-29 | Oxford J Craig | Apparatus and method for broad spectrum radiation attenuation |
| EP3127921A1 (en) * | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
| AR082163A1 (es) | 2010-07-15 | 2012-11-14 | Hoffmann La Roche | Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos |
| AT510032B1 (de) | 2010-11-30 | 2012-01-15 | Steiner Erwin Ing | Montageeinrichtung für fassadenelemente |
| US9100245B1 (en) | 2012-02-08 | 2015-08-04 | Amazon Technologies, Inc. | Identifying protected media files |
| WO2014031718A1 (en) * | 2012-08-23 | 2014-02-27 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to tslp |
| US9306926B2 (en) | 2013-03-15 | 2016-04-05 | Brian A. Truong | User authentication using unique hidden identifiers |
| CN107428828A (zh) * | 2015-03-11 | 2017-12-01 | 葛兰素史密斯克莱知识产权发展有限公司 | Tslp结合蛋白 |
| EP3609917A1 (en) * | 2017-04-12 | 2020-02-19 | Amgen Inc. | Treatment of asthma with anti-tslp antibody |
| CA3066399A1 (en) | 2017-06-08 | 2018-12-13 | Amgen Inc. | Torque driven drug delivery device |
| EA202090399A1 (ru) * | 2017-08-01 | 2020-05-20 | Эмджен Инк. | Системы и способы для подготовки в режиме реального времени образца полипептида для анализа с помощью масс-спектрометрии |
| IL319987A (en) | 2017-11-10 | 2025-06-01 | Amgen Inc | Plungers for drug delivery devices |
| WO2019178151A1 (en) | 2018-03-13 | 2019-09-19 | Amgen Inc. | Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis |
| MA53913A (fr) | 2018-10-15 | 2022-01-19 | Amgen Inc | Procédé d'assemblage de plate-forme pour dispositif d'administration de médicament |
| JP7719714B2 (ja) | 2018-10-15 | 2025-08-06 | アムジエン・インコーポレーテツド | ダンピング機構を有する薬物送達装置 |
| EP4517327A3 (en) | 2019-06-05 | 2025-05-07 | Amgen Inc. | Methods of identifying attributes of therapeutic proteins |
| JP7331298B2 (ja) * | 2019-09-04 | 2023-08-23 | ビオシオン インコーポレイテッド | 抗体結合ｔｓｌｐ及びその使用 |
-
2022
- 2022-04-22 KR KR1020237039566A patent/KR20230175245A/ko active Pending
- 2022-04-22 TW TW111115432A patent/TW202304980A/zh unknown
- 2022-04-22 AR ARP220101043A patent/AR125404A1/es unknown
- 2022-04-22 IL IL307439A patent/IL307439A/en unknown
- 2022-04-22 BR BR112023022041A patent/BR112023022041A2/pt unknown
- 2022-04-22 WO PCT/US2022/025999 patent/WO2022226342A2/en not_active Ceased
- 2022-04-22 AU AU2022262006A patent/AU2022262006A1/en active Pending
- 2022-04-22 EP EP22722641.2A patent/EP4326762A2/en active Pending
- 2022-04-22 CN CN202280030029.7A patent/CN117177992A/zh active Pending
- 2022-04-22 JP JP2023563978A patent/JP2024516595A/ja active Pending
- 2022-04-22 US US18/287,597 patent/US20240182558A1/en active Pending
- 2022-04-22 MX MX2023012325A patent/MX2023012325A/es unknown
- 2022-04-22 CA CA3216700A patent/CA3216700A1/en active Pending
-
2023
- 2023-10-19 CL CL2023003124A patent/CL2023003124A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240182558A1 (en) | 2024-06-06 |
| WO2022226342A3 (en) | 2022-12-01 |
| AR125404A1 (es) | 2023-07-12 |
| EP4326762A2 (en) | 2024-02-28 |
| AU2022262006A1 (en) | 2023-10-19 |
| CA3216700A1 (en) | 2022-10-27 |
| JP2024516595A (ja) | 2024-04-16 |
| IL307439A (en) | 2023-12-01 |
| WO2022226342A2 (en) | 2022-10-27 |
| CN117177992A (zh) | 2023-12-05 |
| TW202304980A (zh) | 2023-02-01 |
| BR112023022041A2 (pt) | 2023-12-26 |
| CL2023003124A1 (es) | 2024-04-26 |
| KR20230175245A (ko) | 2023-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2022226342A3 (en) | Modified anti-tslp antibodies | |
| ZA202209119B (en) | Anti-human cd19 antibodies | |
| WO2020160156A3 (en) | Anti-gal3 antibodies and uses thereof | |
| WO2022032006A3 (en) | Il2rb binding molecules and methods of use | |
| MX2020007945A (es) | Proteinas f del rsv estabilizadas y usos de las mismas. | |
| ZA201802331B (en) | Stable inoculant compositions and methods for producing same | |
| MX2020013421A (es) | Composiciones de dióxido de silicio de carbono poroso biogénico, métodos de elaboracion y uso de estas. | |
| MX2023014154A (es) | Anticuerpos anti-ccr8. | |
| WO2022040088A3 (en) | Cd45 binding molecules and methods of use | |
| TR201901841T4 (tr) | Her antikorlarının sabit dozlaması. | |
| EA200802168A1 (ru) | Гуманизированное антитело к с-kit | |
| MX2015012562A (es) | Purificacion de conjugados anticuerpo-farmaco (cafs). | |
| WO2020068752A8 (en) | SIRPα BINDING PROTEINS AND METHODS OF USE THEREOF | |
| CR20230531A (es) | Composiciones de anticuerpos anti-tslp y usos de las mismas | |
| PH12021551100A1 (en) | Dried biological compositions and methods thereof | |
| MX2024001644A (es) | Anticuerpos contra el receptor alfa de la interleucina-4 humana. | |
| MX2021000287A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente. | |
| MX2024015494A (es) | Formulación de anticuerpos anti-c1s del complemento | |
| ZA202401405B (en) | Compositions and methods for anti-pacap antibodies | |
| WO2022032005A3 (en) | Il10rb binding molecules and methods of use | |
| MX2022012229A (es) | Composiciones de anticuerpo anti cd6 y metodos para tratar y reducir efectos negativos de un coronavirus incluyendo a covid 19. | |
| EA200601894A1 (ru) | Производные пиперазинилпиперидина в качестве антагонистов хемокинового рецептора | |
| MX2024005683A (es) | Anticuerpos contra el factor de necrosis tumoral alfa humano. | |
| WO2021011779A3 (en) | Mesenchymal stem cell compositions | |
| MX2024015561A (es) | Composicion de alulosa con estabilidad excelente |